MartyC has been a big fan of Sangamo's manufacturing build-out and an even bigger defender of the company's R&D spend... but how much has/does that in-house mfg operation cost ?

as we all know, all those "Manufacturing & TechOps" expenses are buried in what's been reported as "pre-clinical wholly owned R&D"... a category that was $117M (> 50%) of the total R&D spend of $231M in 2021

MartyC has also posted that as of 12/31/21 "Sangamo has 163 (mfg) ees split between France and CA" vs a total headcount of 431 employees... and he notes that Sangamo "has already improved the (SCD) manufacturing process" as evidence that the in-house initiative is paying-off (whereas it's been my understanding that SNY had already developed those improvements)

so let's get digital... how much of the prior years "pre-clinical wholly owned R&D" ($37M in 2019, $79M in 2020, $117M in 2021, and $xxxM for 2022) has been in-house mfg related rather than what has sounded like "cutting edge research for the infinite pipeline" ?

and with 163 ees, I'll bet that its cost is substantially more that anyone here has expected or assumed... but that no one will care :-)